resolver

Patel, J.H., Cobbold, J.F., Thomas, H.C., Taylor-Robinson, S.D. (2010). Hepatitis C
and hepatic steatosis. QJM. 4. Epub ahead of print
Pattullo, V., Ravindran, N.C., Mazzulli, T., Wong, D.K., Heathcote, E.J. (2010).
Pegylated interferon plus optimized weight-based ribavirin dosing negate the
influence of weight and body mass index on early viral kinetics and sustained
virological response in chronic hepatitis C. J Viral Hepat. 23. Epub ahead of print
Pedersen-Bjergaard, U., Host, U., Kelbaek, H., Schifter, S., Rehfeld, J.F., Faber, J.,
Christensen, N.J. (1996). Influence of meal composition on postprandial peripheral
plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest. 56,
497-503
Pittner, R.A., Moore, C.X., Bhavsar, S.P., Gedulin, B.R., Smith, P.A., Jodka, C.M.,
Parkes, D.G., Paterniti, J.R., Srivastava, V.P., Young. A.A. (2004). Effects of
PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord.
28, 963-971
Reddy, K.R., Govindarajan, S., Marcellin, P., Bernstein, D., Dienstag, J.L.,
Bodenheimer, H., Rakela, J., Messinger, D., Schmidt, G., Ackrill, A., Hadziyannis,
S.J. (2008). Hepatic steatosis in chronic hepatitis C: baseline host and viral
characteristics and influence on response to therapy with peginterferon alpha-2a plus
ribavirin. J Viral Hepat. 15, 129-136
Rehermann, B., Nascimbeni, M. (2005). Immunology of hepatitis B virus and
hepatitis C virus infection. Nat Rev Immunol. 5, 215-229
Robert Koch Institut. (2009). Epidemiologisches Bulletin. 50, 513-524
Roche Pharma AG. (2009). Fachinformation Copegus. 10, 1-13
Roche Pharma AG. (2009). Fachinformation Pegasys. 10, 1-14
81